Changes in Hong Kong stocks | Zaiding Pharmaceutical (09688) rose nearly 5% in early trading DLL3 ADC launches first-line SCLC Global Phase III clinical trial

The Zhitong Finance App learned that Zaiding Pharmaceutical (09688) rose nearly 5% in early trading. As of press release, it rose 3.60% to HK$20.14, with a turnover of HK$158.619 million.

According to the news, on August 31, Zaiding Pharmaceutical registered a global phase III clinical trial of ZL-1310+ PD-L1 antibody first-line treatment for ES-SCLC on the ClinicalTrials.gov website. The global phase III clinical trial is intended to enroll 530 first-line ES-SCLC patients and is expected to be initially completed in June 2030.

CITIC Construction Investment previously released a research report stating that the company's independent R&D assets are gradually entering the clinical value verification stage, and the core self-research pipeline is expected to usher in intensive data readings and key R&D progress within the year. Important catalysts for the second half of 2026 include: publication of Zoci (ZL-1310, DLL3 ADC) first-line small cell lung cancer (1L SCLC) combination treatment data, promotion of 1L SCLC and extrapulmonary neuroendocrine cancer (ep NE C) registration development; and publication of the first human data on ZL-1503 (IL-13×IL-31Rα double antibody).